---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-111585"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T09:00:08.058681+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Merck Q3 revenue $16.0B (+7%), KEYTRUDA up 17%; cuts FY EPS guidance on $5.5B Daiichi Sankyo charge

## Summary
- Q3 total sales $16.0B (+7% YoY); GAAP EPS $1.86, Non-GAAP EPS $2.13 (+15% YoY).
- KEYTRUDA sales $6.3B (+17%); GARDASIL/GARDASIL 9 sales $2.6B (+13%).
- Full-year 2023 sales guidance raised to $59.7-$60.2B; Non-GAAP EPS guidance lowered to $1.33-$1.38 due to $5.5B upfront charge from Daiichi Sankyo collaboration.
- Entered collaboration with Daiichi Sankyo for three clinical-stage ADC candidates; upfront payment $5.5B.
- FDA approved KEYTRUDA for perioperative NSCLC; priority review for sotatercept (PDUFA March 26, 2024).

## SEC filing metadata
- accession: 0001104659-23-111585
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/0001104659-23-111585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/tm2328962d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-111585
- JSON: https://secwatch.observer/filing/0001104659-23-111585.json
- Plain text: https://secwatch.observer/filing/0001104659-23-111585.txt

## Key facts
- Earnings Releases
  Merck & Co., Inc. updated its the third quarter of 2023 guidance (raised).
  - Period: the third quarter of 2023
  - Guidance: raised
  - Result: reported results
  source text: Incorporated by reference is a press release issued by Merck & Co., Inc. on October 26, 2023, regarding earnings for the third quarter of 2023, attached as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/310158/000110465923111585/0001104659-23-111585-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.